Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-08
2008-01-08
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S651000, C546S157000, C564S355000, C564S086000, C564S196000
Reexamination Certificate
active
11185295
ABSTRACT:
The invention provides novel β2adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 4894219 (1990-01-01), Baker et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 5064863 (1991-11-01), Alig et al.
patent: 5977154 (1999-11-01), Bell et al.
patent: 6346532 (2002-02-01), Maruyama et al.
patent: 6436914 (2002-08-01), Sher et al.
patent: 6541669 (2003-04-01), Moran et al.
patent: 6576793 (2003-06-01), Moran et al.
patent: 6653323 (2003-11-01), Moran et al.
patent: 6670376 (2003-12-01), Moran et al.
patent: 7037938 (2006-05-01), Hattori et al.
patent: 2002/0022625 (2002-02-01), Walland et al.
patent: 2002/0143034 (2002-10-01), Taniguchi et al.
patent: 2003/0229058 (2003-12-01), Moran et al.
patent: 2004/0059116 (2004-03-01), Moran et al.
patent: 2004/0063755 (2004-04-01), Moran et al.
patent: 2004/0242890 (2004-12-01), Coe et al.
patent: 2005/0113411 (2005-05-01), Linsell et al.
patent: 2005/0159448 (2005-07-01), McKinnell et al.
patent: 0 147 719 (1985-07-01), None
patent: 1 463 219 (1977-02-01), None
patent: WO 00/40560 (2000-07-01), None
patent: WO 01/07026 (2001-02-01), None
patent: WO 01/35947 (2001-05-01), None
patent: WO 01/36413 (2001-05-01), None
patent: WO 01/42193 (2001-06-01), None
patent: WO02/00622 (2002-01-01), None
patent: WO 02/00622 (2002-01-01), None
patent: WO 02/06276 (2002-01-01), None
patent: WO 02/38544 (2002-05-01), None
patent: WO 03/024439 (2003-03-01), None
patent: WO2003-EP8824 (2003-08-01), None
patent: WO 2004/002939 (2004-01-01), None
patent: WO 2004/016578 (2004-02-01), None
patent: WO 2004/016601 (2004-02-01), None
STN search abstract of Journal of Bioorganic and Medicinal Chemistr Letters (2004), 14(18), 4705-10.
Alikhani et al., “Long-chain formoterol analogues: an investigation into the effect of increasing amino-substutuent chain length on the β2-adrenoceptor activity”, Bioorganic & Medicinal Chemistry Letters, 14, pp. 4705-4710 (2004).
Bompart et al., “Synthesis of new β-blockers analogs of bevantolol”, Annales Pharmaceutiques Francaises, vol. Date 1984, 42(6), pp. 537-545 (1985) (In French with English abstract).
Bompart et al., “Synthesis of new β-blockers analogous of the bevantolol or the alprenolol”, Annales Pharmaceutiques Francaises, vol. Date 1987, 45(5), pp. 379-387 (1988) (In French with English abstract).
Deyrup et al., “Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the Beta2-adrenoceptor”, Naunyn-Schmiedeberg's Arch Pharmacol (1999) 359:168-177.
Fotsch et al., “Synthesis and Structure-Activity Relationships of Trisubstituted Phenyl Urea Derivatives as Neuropeptide Y5 Receptor antagonists”, J. Med. Chem., (2001), 44:2344-2356.
Isogaya et al., “Binding Pockets of the β1- and β2-Adrenergic Receptors for Subtype-Selective Agonists”, Molecular Pharmacology, vol. 56, pp. 875-885 (1999).
Milecki et al., “Carbostyril Derivatives Having Potent β-Adrenergic Agonist Properties”, J. Med. Chem, (1987), 30, 1563-1566.
Shuker et al., “The Application of High-Throughput Synthesis and Purification to the Preparation of Ethanolamines”, Tetrahedron Letters, (1997), 38(35):6149-6152.
Yokoi et al., “The Development of a Radioimmunoassay for Formoterol”, Life Sciences, (1983) vol. 33, No. 17, pp. 1665-1672.
Yoshizaki et al., “Sympathomimetic Amines Having a Carbostyril Nucleus”, J. Med. Chem., (1976), vol. 19, No. 9, pp. 1138-1142.
McKinnell Robert Murray
Moran Edmund J.
Anderson Rebecca
Chu Yong
Hagenah Jeffrey A.
Saxon Roberta P.
Theravance Inc.
LandOfFree
Diaryl ether β2 adrenergic receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diaryl ether β2 adrenergic receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diaryl ether β2 adrenergic receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3949287